{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:23:26Z","timestamp":1792805006865,"version":"4.5.0"},"reference-count":84,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Center for Advancing Translational Sciences (NCATS)","award":["UL1 TR001866"],"award-info":[{"award-number":["UL1 TR001866"]}],"id":[{"id":"https:\/\/ror.org\/04pw6fb54","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Preeclampsia is one of the leading causes of maternal and perinatal morbidity and mortality worldwide. In recent decades, many studies have evaluated different interventions in order to prevent the occurrence of preeclampsia. Among these, administration of low-dose aspirin from early pregnancy showed consistent evidence of its prophylactic role. In this article, we review the scientific literature on this topic, highlighting the rationale for aspirin use, who should be treated, the timing of initiation and cessation of therapy, the importance of proper dosing, and its role in the prevention of other adverse outcomes.<\/jats:p>","DOI":"10.3390\/jcm13154427","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T12:27:43Z","timestamp":1722256063000},"page":"4427","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Controversies and Clarifications Regarding the Role of Aspirin in Preeclampsia Prevention: A Focused Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5261-9277","authenticated-orcid":false,"given":"Amihai","family":"Rottenstreich","sequence":"first","affiliation":[{"name":"Laboratory of Blood and Vascular Biology, Rockefeller University, New York, NY 10065, USA"},{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Zucker School of Medicine at Hofstra\/Northwell, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"ref_1","unstructured":"Maternal Mortality Collaborators GBD (2016). Global, regional, and national levels of maternal mortality, 1990\u20132015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet, 388, 1775\u20131812."},{"key":"ref_2","unstructured":"Child Mortality Collaborators GBD (2016). Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980\u20132015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet, 388, 1725\u20131774."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1056\/NEJMoa0706475","article-title":"Long-term medical and social consequences of preterm birth","volume":"359","author":"Moster","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/S0140-6736(00)02384-9","article-title":"Adult cardiovascular risk factors in premature babies","volume":"355","author":"Irving","year":"2000","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e003497","DOI":"10.1161\/CIRCOUTCOMES.116.003497","article-title":"Preeclampsia and future cardiovascular health: A systematic review and metaanalysis","volume":"10","author":"Wu","year":"2017","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/uog.17534","article-title":"Decreased endothelial function and increased subclinical heart failure in women several years after pre-eclampsia","volume":"52","author":"Breetveld","year":"2018","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1161\/HYPERTENSIONAHA.109.130765","article-title":"Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother","volume":"53","author":"Lykke","year":"2009","journal-title":"Hypertension"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjh.14520","article-title":"The aspirin story\u2014From willow to wonder drug","volume":"177","author":"Desborough","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0002-9610(49)90394-3","article-title":"The Ebers papyrus","volume":"77","author":"Cunha","year":"1949","journal-title":"Am. J. Surg."},{"key":"ref_10","first-page":"179","article-title":"The discovery of aspirin\u2019s antithrombotic effects","volume":"34","author":"Miner","year":"2007","journal-title":"Tex. Heart Inst. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2018.10.008","article-title":"The first 3500 years of aspirin history from its roots\u2014A concise summary","volume":"113","author":"Montinari","year":"2019","journal-title":"Vasc. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nat. New Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","article-title":"The mechanism of action of aspirin","volume":"110","author":"Vane","year":"2003","journal-title":"Thromb. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1016\/j.ajpath.2016.08.010","article-title":"Low-dose acetylsalicylic acid treatment modulates the production of cytokines and improves trophoblast function in an in vitro model of early-onset preeclampsia","volume":"186","author":"Panagodage","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(78)91367-3","article-title":"Aspirin for the treatment of recurrent toxaemia","volume":"2","author":"Goodlin","year":"1978","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0140-6736(85)92207-X","article-title":"Prevention of pre-eclampsia by early antiplatelet therapy","volume":"1","author":"Beaufils","year":"1985","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(07)60712-0","article-title":"Antiplatelet agents for prevention of pre-eclampsia: A meta-analysis of individual patient data","volume":"369","author":"Askie","year":"2007","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/AOG.0b013e3181e9322a","article-title":"Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-analysis","volume":"116","author":"Bujold","year":"2010","journal-title":"Obstet. Gynecol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000336662","article-title":"Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: A systematic review and meta-analysis","volume":"31","author":"Roberge","year":"2012","journal-title":"Fetal Diagn. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajog.2016.09.076","article-title":"The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: Systematic review and meta-analysis","volume":"216","author":"Roberge","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ajog.2017.12.238","article-title":"Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage","volume":"218","author":"Roberge","year":"2018","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"(2020). Gestational Hypertension and Preeclampsia. ACOG Practice Bulletin, Number 222. Obstet. Gynecol., 135, e237\u2013e260.","DOI":"10.1097\/AOG.0000000000003891"},{"key":"ref_23","unstructured":"(2018). Low-dose aspirin use during pregnancy. ACOG Committee Opinion No. 743. American College of Obstetricians and Gynecologists. Obstet. Gynecol., 132, e44\u2013e52."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jama.2021.14781","article-title":"Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force Recommendation Statement. US Preventive Services Task Force","volume":"326","author":"Force","year":"2021","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/uog.19039","article-title":"Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: Results of SPREE","volume":"51","author":"Tan","year":"2018","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"101297","DOI":"10.1016\/j.ajogmf.2024.101297","article-title":"The IRELAnD study-investigating the role of early low-dose aspirin in diabetes mellitus: A double-blinded, placebo-controlled, randomized trial","volume":"6","author":"Finnegan","year":"2024","journal-title":"Am. J. Obstet. Gynecol. MFM"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.2337\/dc21-1182","article-title":"Unchanged Prevalence of Preeclampsia After Implementation of Prophylactic Aspirin for All Pregnant Women With Preexisting Diabetes: A Prospective Cohort Study","volume":"44","author":"Do","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ajog.2022.09.046","article-title":"Low-dose aspirin for the prevention of superimposed preeclampsia in women with chronic hypertension: A systematic review and meta-analysis","volume":"228","author":"Richards","year":"2023","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/uog.23668","article-title":"ASPRE trial: Risk factors for development of preterm pre-eclampsia despite aspirin prophylaxis","volume":"58","author":"Shen","year":"2021","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_30","unstructured":"(2024, May 22). Available online: https:\/\/fetalmedicine.org\/research\/assess\/preeclampsia\/first-trimester."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijgo.12802","article-title":"The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention","volume":"145","author":"Poon","year":"2019","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/uog.17399","article-title":"Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11\u201313 weeks\u2019 gestation","volume":"49","author":"Wright","year":"2017","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/uog.15807","article-title":"Contingent screening for preterm pre-eclampsia","volume":"47","author":"Wright","year":"2016","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"141.e1","DOI":"10.1016\/j.ajog.2016.09.086","article-title":"Should we recommend universal aspirin for all pregnant women?","volume":"216","author":"Mone","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/AOG.0000000000003413","article-title":"Strategies for prescribing aspirin to prevent preeclampsia: A cost-effectiveness analysis","volume":"134","author":"Mallampati","year":"2019","journal-title":"Obstet. Gynecol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/AOG.0000000000005429","article-title":"Aspirin in Pregnancy","volume":"142","author":"Pullins","year":"2023","journal-title":"Obstet. Gynecol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S1120","DOI":"10.1016\/j.ajog.2021.10.038","article-title":"When to give aspirin to prevent preeclampsia: Application of Bayesian decision theory","volume":"226","author":"Wright","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejogrb.2022.12.032","article-title":"Clinical practice guidelines on the use of aspirin in pregnancy: Systematic review","volume":"282","author":"Alameddine","year":"2023","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101000","DOI":"10.1016\/j.ajogmf.2023.101000","article-title":"Comparing aspirin 75 to 81 mg vs 150 to 162 mg for prevention of preterm preeclampsia: Systematic review and meta-analysis","volume":"5","author":"Ghesquiere","year":"2023","journal-title":"Am. J. Obstet. Gynecol. MFM"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S1701-2163(16)34346-8","article-title":"Low-dose ASA response using the PFA-100 in women with high-risk pregnancy","volume":"31","author":"Caron","year":"2009","journal-title":"J. Obstet. Gynaecol. Can."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"255.e1","DOI":"10.1016\/j.ajog.2019.04.027","article-title":"A pharmacokinetic assessment of optimal dosing, preparation, and chronotherapy of aspirin in pregnancy","volume":"221","author":"Shanmugalingam","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"SMFM Patient Safety and Quality Committee, Combs, C.A., and Montgomery, D.M. (2020). Society for Maternal-Fetal Medicine special statement: Checklists for preeclampsia risk-factor screening to guide recommendations for prophylactic low-dose aspirin. Am. J. Obstet. Gynecol., 223, B7\u2013B11.","DOI":"10.1016\/j.ajog.2020.06.003"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(18)31133-4","article-title":"Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: Analysis of individual patient data from randomised trials","volume":"392","author":"Rothwell","year":"2018","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"385.e1","DOI":"10.1016\/j.ajog.2019.01.222","article-title":"Obesity and laboratory aspirin resistance in high-risk pregnant women treated with low-dose aspirin","volume":"220","author":"Finneran","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Boelig, R.C., Kaushal, G., Rochani, A., McKenzie, S.E., and Kraft, W.K. (2023). Aspirin pharmacokinetics and pharmacodynamics through gestation. Am. J. Obstet. Gynecol., in press.","DOI":"10.1016\/j.ajog.2023.12.028"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.preghy.2018.05.004","article-title":"The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice","volume":"13","author":"Brown","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/09537104.2015.1107536","article-title":"Evening intake of aspirin is associated with a more stable 24-h platelet inhibition compared to morning intake: A study in chronic aspirin users","volume":"27","author":"Fuijkschot","year":"2016","journal-title":"Platelets"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1160\/th14-05-0453","article-title":"Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial","volume":"112","author":"Bonten","year":"2014","journal-title":"Thromb. Haemost."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1161\/HYPERTENSIONAHA.109.134825","article-title":"Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines","volume":"54","author":"Snoep","year":"2009","journal-title":"Hypertension"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1161\/01.HYP.34.4.1016","article-title":"Administration time-dependent effects of aspirin in women at differing risk for preeclampsia","volume":"34","author":"Hermida","year":"1999","journal-title":"Hypertension"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/07420528.2012.717455","article-title":"Chronotherapy with low-dose aspirin for prevention of complications in pregnancy","volume":"30","author":"Ayala","year":"2013","journal-title":"Chronobiol. Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ajog.2016.10.016","article-title":"Antiplatelet therapy before or after 16 weeks\u2019 gestation for preventing preeclampsia: An individual participant data meta-analysis","volume":"216","author":"Meher","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"741.e1","DOI":"10.1016\/j.ajog.2020.05.026","article-title":"Platelet activation and placenta-mediated adverse pregnancy outcomes: An ancillary study to the Effects of Aspirin in Gestation and Reproduction trial","volume":"223","author":"Theilen","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ajog.2019.08.047","article-title":"Does low-dose aspirin initiated before 11 weeks\u2019 gestation reduce the rate of preeclampsia?","volume":"222","author":"Chaemsaithong","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_56","first-page":"15119","article-title":"Diagnosis and management of hypertension in pregnancy: Summary of updated NICE guidance","volume":"366","author":"Webster","year":"2019","journal-title":"BMJ"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jama.2023.0691","article-title":"Aspirin discontinuation at 24 to 28\u2009weeks\u2019 gestation in pregnancies at high risk of preterm preeclampsia: A randomized clinical trial","volume":"329","author":"Mendoza","year":"2023","journal-title":"JAMA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/1471-0528.17631","article-title":"Mid-trimester uterine artery Doppler for aspirin discontinuation in pregnancies at high risk for preterm pre-eclampsia: Post-hoc analysis of StopPRE trial","volume":"131","author":"Bonacina","year":"2023","journal-title":"BJOG"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/uog.12421","article-title":"Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: A meta-analysis","volume":"41","author":"Roberge","year":"2013","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S855","DOI":"10.1016\/j.ajog.2017.12.004","article-title":"Evidence-based national guidelines for the management of suspected fetal growth restriction: Comparison, consensus, and controversy","volume":"218","author":"McCowan","year":"2018","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/AOG.0000000000001848","article-title":"Antiplatelet agents and the Prevention of spontaneous Preterm Birth: A systematic review and Meta-analysis","volume":"129","author":"Askie","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"399.e1","DOI":"10.1016\/j.ajog.2018.06.011","article-title":"Low-dose aspirin is associated with reduced spontaneous preterm birth in nulliparous women","volume":"219","author":"Andrikopoulou","year":"2018","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"336.e1","DOI":"10.1016\/j.ajog.2022.09.006","article-title":"Low- dose aspirin use in pregnancy and the risk of preterm birth: A Swedish register-based cohort study","volume":"228","author":"Kupka","year":"2023","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/HYPERTENSIONAHA.118.11191","article-title":"Cardiovascular system in preeclampsia and beyond","volume":"73","author":"Thilaganathan","year":"2019","journal-title":"Hypertension"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Feng, Y., Lau, S., Chen, Q., Oyston, C., Groom, K., Barrett, C.J., and Chamley, L.W. (2023). Normotensive placental extracellular vesicles provide long-term protection against hypertension and cardiovascular disease. Am. J. Obstet. Gynecol., in press.","DOI":"10.1016\/j.ajog.2023.12.030"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1001\/jama.2023.21523","article-title":"Long-term blood pressure control after hypertensive pregnancy following physician-optimized self-management: The POP-HT randomized clinical trial","volume":"330","author":"Kitt","year":"2023","journal-title":"JAMA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/CIRCULATIONAHA.123.067597","article-title":"Cardiac remodeling after hypertensive pregnancy following physician-optimized blood pressure self-management: The POP-HT randomized clinical trial imaging substudy","volume":"149","author":"Kitt","year":"2024","journal-title":"Circulation"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"125.e1","DOI":"10.1016\/j.ajog.2008.04.016","article-title":"Morbidity associated with sickle cell disease in pregnancy","volume":"199","author":"Villers","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1515\/jpm-2013-0275","article-title":"Sickle cell disease and pregnancy outcomes: Population-based study on 8.8 million births","volume":"42","author":"Alayed","year":"2014","journal-title":"J. Perinat. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2014-11-607317","article-title":"Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: Systematic review and meta-analysis","volume":"125","author":"Meeks","year":"2015","journal-title":"Blood"},{"key":"ref_71","unstructured":"(2024, May 23). ACOG Practice Advisory. Hemoglobinopathies in Pregnancy. August 2022., Available online: https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2022\/08\/hemoglobinopathies-in-pregnancy."},{"key":"ref_72","unstructured":"(2024, May 23). RCOG Green-Top Guideline. No. 61. Management of Sickle Cell Disease in Pregnancy. Available online: https:\/\/www.rcog.org.uk\/media\/nyinaztx\/gtg_61.pdf."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/hematology.2022000378","article-title":"Evidence-based management of pregnant women with sickle cell disease in high-income countries","volume":"2022","author":"Shangaris","year":"2022","journal-title":"Hematology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1182\/blood.2023020728","article-title":"How I Treat Sickle Cell Disease in Pregnancy","volume":"143","author":"James","year":"2024","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/bloodadvances.2023011636","article-title":"Pregnancy outcomes and iron status in \u03b2-thalassemia major and intermedia: A systematic review and meta-analysis","volume":"8","author":"Vlachodimitropoulou","year":"2024","journal-title":"Blood Adv."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/ajh.25270","article-title":"Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger","volume":"93","author":"Szuber","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood.2023020729","article-title":"How I treat myeloproliferative neoplasms in pregnancy","volume":"143","author":"Robinson","year":"2024","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/bjh.14290","article-title":"Myeloproliferative neoplasms in pregnancy: Ways to go","volume":"175","author":"Lavi","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e1912666","DOI":"10.1001\/jamanetworkopen.2019.12666","article-title":"Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: A systematic review and meta-analysis","volume":"2","author":"Maze","year":"2019","journal-title":"JAMA Netw. Open."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"106459","DOI":"10.1016\/j.leukres.2020.106459","article-title":"Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia","volume":"98","author":"How","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/17474086.2018.1506325","article-title":"Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy","volume":"11","author":"Griesshammer","year":"2018","journal-title":"Expert. Rev. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/ajh.26067","article-title":"Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations","volume":"96","author":"Gangat","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11239-018-1663-9","article-title":"The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis","volume":"46","author":"Rottenstreich","year":"2018","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bjh.18856","article-title":"Assessment-based management of placenta-mediated pregnancy complications: Pragmatism until a precision medicine approach evolves","volume":"202","author":"Brenner","year":"2023","journal-title":"Br. J. Haematol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/15\/4427\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:25:39Z","timestamp":1760109939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/15\/4427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":84,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["jcm13154427"],"URL":"https:\/\/doi.org\/10.3390\/jcm13154427","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]}}}